ArticleFrontiers in oncology2022

Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma.

Xiaoxuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.